Friday, May 26, 2023
ME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces clinical update on survival of newly diagnosed glioblastoma patients in the GLORIA expansion arm evaluating NOX-A12, TME Pharma's CXCL12 inhibitor, in combination with standard of care radiotherapy and anti-VEGF, bevacizumab.
After 14 months on study (median), 83% of GLORIA expansion arm patients (5 of 6) are still alive. As long as treatment or follow-up for these patients is ongoing, median overall survival (mOS) will continue to improve.1 As a reference, the expected median overall survival for patients under current standard of care with chemotherapy refractory tumors (MGMT unmethylated) and whose tumor remains detectable after surgical intervention is approximately 10 months.2
"The fact that the glioblastoma patients are 14 months on study and median overall survival will continue to improve is a very positive clinical development. It demonstrates a clinically meaningful improvement over the 10-month expected survival rate for this patient population as well as the median overall survival of 12.7 months achieved in the GLORIA cohort treated with NOX-A12 and radiotherapy alone," said Aram Mangasarian, CEO of TME Pharma. "The latest survival data from the treatment combination of NOX-A12 with radiotherapy and bevacizumab continues to validate our therapeutic approach, demonstrates a highly encouraging trend towards prolonged overall survival and underlines the potential for superior benefit of this treatment combination for glioblastoma patients. We believe that this further improves the profile of NOX-A12 for partnering discussions and for access to accelerated regulatory pathways in glioblastoma, which we estimate to be $2.5 billion per year addressable market. We are looking forward to providing more clinical updates as the data mature."